カテゴリー： Transparency Market Research, 世界, 医療/バイオ

末梢血管拡張薬の世界市場2023～2031：薬剤別

◆英語タイトル：Peripheral Vasodilator Drugs Market (Drug Type: Calcium Channel Blockers, Direct-acting Vasodilators, Alpha-adrenergic Blockers, Potassium Channel Activators, Nitrates, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Transparency Market Researchが発行した調査報告書（TMR23MA064）◆商品コード：TMR23MA064
◆発行会社（リサーチ会社）：Transparency Market Research
◆発行日：2023年3月13日
◆ページ数：130
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD5,795 ⇒換算￥869,250見積依頼/購入/質問フォーム
Multi User（5名様閲覧）USD8,795 ⇒換算￥1,319,250見積依頼/購入/質問フォーム
Corporate License（法人閲覧）USD11,795 ⇒換算￥1,769,250見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Transparency Market Research社の当調査レポートでは、世界の末梢血管拡張薬市場規模が、2023年の60億ドルから2031年に90億ドルとなり、予測期間中に年平均成長率5.3%で拡大すると展望しています。本書は、末梢血管拡張薬の世界市場にフォーカスし、市場状況や今後の動向などをまとめた資料です。序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、薬剤別（カルシウムチャネル拮抗薬、直接作用型血管拡張薬、αアドレナリン拮抗薬、カリウムチャネル活性化剤、その他）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況など、以下の構成で掲載しています。また、市場参入企業として、Pfizer, Inc.、Novartis AG、GSK plc、AstraZeneca、Merck & Co., Inc.、Sanofi、Bayer AG、Abbott Laboratories、Bristol-Myers Squibb Company、Boehringer Ingelheim International GmbH、Teva Pharmaceutical Industries Ltd.、Viatris, Inc.、Sun Pharmaceutical Industries Ltd.、Lupinなどの情報が含まれています。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・主要インサイト
・世界の末梢血管拡張薬市場規模：薬剤別
- カルシウムチャネル拮抗薬の市場規模
- 直接作用型血管拡張薬の市場規模
- αアドレナリン拮抗薬の市場規模
- カリウムチャネル活性化剤の市場規模
- その他薬剤の市場規模
・世界の末梢血管拡張薬市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- 小売薬局チャネルの市場規模
- オンライン薬局チャネルの市場規模
・世界の末梢血管拡張薬市場規模：地域別
- 北米の末梢血管拡張薬市場規模
- ヨーロッパの末梢血管拡張薬市場規模
- アジア太平洋の末梢血管拡張薬市場規模
- 中南米の末梢血管拡張薬市場規模
- 中東・アフリカの末梢血管拡張薬市場規模
・競争状況

Peripheral Vasodilator Drugs Market – Scope of Report
TMR’s report on the global peripheral vasodilator drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global peripheral vasodilator drugs market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global peripheral vasodilator drugs market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the peripheral vasodilator drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global peripheral vasodilator drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global peripheral vasodilator drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global peripheral vasodilator drugs market.

The report delves into the competitive landscape of the global peripheral vasodilator drugs market. Key players operating in the global peripheral vasodilator drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global peripheral vasodilator drugs market profiled in this report.

Key Questions Answered in Global Peripheral Vasodilator Drugs Market Report
• What is the sales/revenue generated by peripheral vasodilator drugs across all regions during the forecast period?
• What are the opportunities in the global peripheral vasodilator drugs market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Peripheral Vasodilator Drugs Market – Research Objectives and Research Approach
The comprehensive report on the global peripheral vasodilator drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global peripheral vasodilator drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global peripheral vasodilator drugs market.

❖ レポートの目次 ❖

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Peripheral Vasodilator Drugs Market
4. Market Overview
    4.1. Introduction
        4.1.1. Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Peripheral Vasodilator Drugs Market Analysis and Forecast, 2017–2031
        4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
    5.1. Disease Prevalence & Incidence Rate globally with key countries
    5.2. Regulatory Scenario by Region/globally
    5.3. COVID-19 Pandemics Impact on Industry
6. Global Peripheral Vasodilator Drugs Market Analysis and Forecast, by Drug Type
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast, by Drug Type, 2017–2031
        6.3.1. Calcium Channel Blockers
        6.3.2. Direct-acting Vasodilators
        6.3.3. Alpha-adrenergic Blockers
        6.3.4. Potassium Channel Activators
        6.3.5. Nitrates
        6.3.6. Others
    6.4. Market Attractiveness Analysis, by Drug Type
7. Global Peripheral Vasodilator Drugs Market Analysis and Forecast, by Distribution Channel
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Distribution Channel, 2017–2031
        7.3.1. Hospital Pharmacies
        7.3.2. Retail Pharmacies
        7.3.3. Online Pharmacies
    7.4. Market Attractiveness Analysis, by Distribution Channel
8. Global Peripheral Vasodilator Drugs Market Analysis and Forecast, by Region
    8.1. Key Findings
    8.2. Market Value Forecast, by Region
        8.2.1. North America
        8.2.2. Europe
        8.2.3. Asia Pacific
        8.2.4. Latin America
        8.2.5. Middle East & Africa
    8.3. Market Attractiveness Analysis, by Region
9. North America Peripheral Vasodilator Drugs Market Analysis and Forecast
    9.1. Introduction
        9.1.1. Key Findings
    9.2. Market Value Forecast, by Drug Type, 2017–2031
        9.2.1. Calcium Channel Blockers
        9.2.2. Direct-acting Vasodilators
        9.2.3. Alpha-adrenergic Blockers
        9.2.4. Potassium Channel Activators
        9.2.5. Nitrates
        9.2.6. Others
    9.3. Market Value Forecast, by Distribution Channel, 2017–2031
        9.3.1. Hospital Pharmacies
        9.3.2. Retail Pharmacies
        9.3.3. Online Pharmacies
    9.4. Market Value Forecast, by Country, 2017–2031
        9.4.1. U.S.
        9.4.2. Canada
    9.5. Market Attractiveness Analysis
        9.5.1. By Drug Type
        9.5.2. By Distribution Channel
        9.5.3. By Country
10. Europe Peripheral Vasodilator Drugs Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Drug Type, 2017–2031
        10.2.1. Calcium Channel Blockers
        10.2.2. Direct-acting Vasodilators
        10.2.3. Alpha-adrenergic Blockers
        10.2.4. Potassium Channel Activators
        10.2.5. Nitrates
        10.2.6. Others
    10.3. Market Value Forecast, by Distribution Channel, 2017–2031
        10.3.1. Hospital Pharmacies
        10.3.2. Retail Pharmacies
        10.3.3. Online Pharmacies
    10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
        10.4.1. Germany
        10.4.2. U.K.
        10.4.3. France
        10.4.4. Spain
        10.4.5. Italy
        10.4.6. Rest of Europe
    10.5. Market Attractiveness Analysis
        10.5.1. By Drug Type
        10.5.2. By Distribution Channel
        10.5.3. By Country/Sub-region
11. Asia Pacific Peripheral Vasodilator Drugs Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Drug Type, 2017–2031
        11.2.1. Calcium Channel Blockers
        11.2.2. Direct-acting Vasodilators
        11.2.3. Alpha-adrenergic Blockers
        11.2.4. Potassium Channel Activators
        11.2.5. Nitrates
        11.2.6. Others
    11.3. Market Value Forecast, by Distribution Channel, 2017–2031
        11.3.1. Hospital Pharmacies
        11.3.2. Retail Pharmacies
        11.3.3. Online Pharmacies
    11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
        11.4.1. China
        11.4.2. Japan
        11.4.3. India
        11.4.4. Australia & New Zealand
        11.4.5. Rest of Asia Pacific
    11.5. Market Attractiveness Analysis
        11.5.1. By Drug Type
        11.5.2. By Distribution Channel
        11.5.3. By Country/Sub-region
12. Latin America Peripheral Vasodilator Drugs Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Drug Type, 2017–2031
        12.2.1. Calcium Channel Blockers
        12.2.2. Direct-acting Vasodilators
        12.2.3. Alpha-adrenergic Blockers
        12.2.4. Potassium Channel Activators
        12.2.5. Nitrates
        12.2.6. Others
    12.3. Market Value Forecast, by Distribution Channel, 2017–2031
        12.3.1. Hospital Pharmacies
        12.3.2. Retail Pharmacies
        12.3.3. Online Pharmacies
    12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.4.1. Brazil
        12.4.2. Mexico
        12.4.3. Rest of Latin America
    12.5. Market Attractiveness Analysis
        12.5.1. By Drug Type
        12.5.2. By Distribution Channel
        12.5.3. By Country/Sub-region
13. Middle East & Africa Peripheral Vasodilator Drugs Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Drug Type, 2017–2031
        13.2.1. Calcium Channel Blockers
        13.2.2. Direct-acting Vasodilators
        13.2.3. Alpha-adrenergic Blockers
        13.2.4. Potassium Channel Activators
        13.2.5. Nitrates
        13.2.6. Others
    13.3. Market Value Forecast, by Distribution Channel, 2017–2031
        13.3.1. Hospital Pharmacies
        13.3.2. Retail Pharmacies
        13.3.3. Online Pharmacies
    13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.4.1. GCC Countries
        13.4.2. South Africa
        13.4.3. Rest of Middle East & Africa
    13.5. Market Attractiveness Analysis
        13.5.1. By Drug Type
        13.5.2. By Distribution Channel
        13.5.3. By Country/Sub-region
14. Competition Landscape
    14.1. Market Player – Competition Matrix (by tier and size of companies)
    14.2. Market Share Analysis, by Company, 2022
    14.3. Company Profiles
        14.3.1. Pfizer, Inc.
            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.1.2. Product Portfolio
            14.3.1.3. Financial Overview
            14.3.1.4. SWOT Analysis
            14.3.1.5. Strategic Overview
        14.3.2. Novartis AG
            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.2.2. Product Portfolio
            14.3.2.3. Financial Overview
            14.3.2.4. SWOT Analysis
            14.3.2.5. Strategic Overview
        14.3.3. GSK plc
            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.3.2. Product Portfolio
            14.3.3.3. Financial Overview
            14.3.3.4. SWOT Analysis
            14.3.3.5. Strategic Overview
        14.3.4. AstraZeneca
            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.4.2. Product Portfolio
            14.3.4.3. Financial Overview
            14.3.4.4. SWOT Analysis
            14.3.4.5. Strategic Overview
        14.3.5. Merck & Co., Inc.
            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.5.2. Product Portfolio
            14.3.5.3. Financial Overview
            14.3.5.4. SWOT Analysis
            14.3.5.5. Strategic Overview
        14.3.6. Sanofi
            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.6.2. Product Portfolio
            14.3.6.3. Financial Overview
            14.3.6.4. SWOT Analysis
            14.3.6.5. Strategic Overview
        14.3.7. Bayer AG
            14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.7.2. Product Portfolio
            14.3.7.3. Financial Overview
            14.3.7.4. SWOT Analysis
            14.3.7.5. Strategic Overview
        14.3.8. Abbott Laboratories
            14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.8.2. Product Portfolio
            14.3.8.3. Financial Overview
            14.3.8.4. SWOT Analysis
            14.3.8.5. Strategic Overview
        14.3.9. Bristol-Myers Squibb Company
            14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.9.2. Product Portfolio
            14.3.9.3. Financial Overview
            14.3.9.4. SWOT Analysis
            14.3.9.5. Strategic Overview
        14.3.10. Boehringer Ingelheim International GmbH
            14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.10.2. Product Portfolio
            14.3.10.3. Financial Overview
            14.3.10.4. SWOT Analysis
            14.3.10.5. Strategic Overview
        14.3.11. Teva Pharmaceutical Industries Ltd.
            14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.11.2. Product Portfolio
            14.3.11.3. Financial Overview
            14.3.11.4. SWOT Analysis
            14.3.11.5. Strategic Overview
        14.3.12. Viatris, Inc.
            14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.12.2. Product Portfolio
            14.3.12.3. Financial Overview
            14.3.12.4. SWOT Analysis
            14.3.12.5. Strategic Overview
        14.3.13. Sun Pharmaceutical Industries Ltd.
            14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.13.2. Product Portfolio
            14.3.13.3. Financial Overview
            14.3.13.4. SWOT Analysis
            14.3.13.5. Strategic Overview
        14.3.14. Lupin
            14.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.14.2. Product Portfolio
            14.3.14.3. Financial Overview
            14.3.14.4. SWOT Analysis
            14.3.14.5. Strategic Overview

List of Tables

Table 01: Global Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 02: Global Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 03: Global Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 04: North America Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 05: North America Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 06: North America Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 07: Europe Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 08: Europe Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 09: Europe Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Asia Pacific Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 11: Asia Pacific Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 12: Asia Pacific Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 13: Latin America Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 14: Latin America Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 15: Latin America Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 16: Middle East & Africa Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 17: Middle East & Africa Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 18: Middle East & Africa Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 末梢血管拡張薬の世界市場2023～2031：薬剤別(Peripheral Vasodilator Drugs Market (Drug Type: Calcium Channel Blockers, Direct-acting Vasodilators, Alpha-adrenergic Blockers, Potassium Channel Activators, Nitrates, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031)]についてメールでお問い合わせはこちらでお願いします。
グローバルリサーチ調査資料のイメージグローバルリサーチ調査資料のイメージ
◆関連リサーチレポート◆
  • 筋萎縮性側索硬化症（ALS）治療の世界市場2023～2031：種類別、治療別
  • 世界のドライアイ疾患市場2023-2031：製品別（人工涙液、抗炎症薬、シクロスポリン、副腎皮質ステロイド、ライフテグラスト、パンクチュアルプラグ、セクレタグ、その他）
  • 世界のアレルギー免疫療法市場2023-2031：治療法別（皮下免疫療法（SCIT）、舌下免疫療法（SLIT））
  • 世界の頭頸部がん市場2023-2031：薬剤クラス別（EFGR阻害剤、分裂阻害剤、抗PD-1モノクローナル抗体、その他）、流通チャネル別（病院薬局、小売薬局、Eコマース）
  • 高脂血症治療薬の世界市場2023～2031：治療薬種類別、流通チャネル別

    • ◆H&Iグローバルリサーチのお客様（例）◆